The current study is the extension of our previous study and found that the ratio of cellular apoptosis and cell migration as well as intracellular drug concentrations can be controlled by overexpressing or knocking down the expression of FOXM1, providing FOXM1 as a target for the treatment of cervical cancer that is resistant to paclitaxel. The gene discussed is FOXM1; the disease is cervical cancer.